ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2936

All-Trans Retinoic Acid Stabilizes Natural T Regulatory Cells Isolated from Patients with Systemic Lupus Erythematosus Under Inflammatory Conditions

Julie Wang1, Zixuan Qiao2, Feng Huang3, Ya Liu2, Nancy J. Olsen4 and Song Guo Zheng5, 1Medicine, Penn State Hershey Medical Center, Hershey, PA, 2Medicine, Xuzhou Medical University, Xuzhou, China, 3Center for Clinic Immunology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Guangzhou, China, 4Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA, 5Medicine/Rheumatology, Penn State University Hershey Medical Center, Hershey, PA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: inflammation and regulatory cells, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: T Cell Biology and Targets in Autoimmune Disease - Poster Session II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Recent studies have demonstrated that naturally occurring CD4+Foxp3+regulatory T cells (nTregs) are unstable and dysfunctional in the presence of pro-inflammatory cytokines. All-trans RA (atRA), the active derivative of vitamin A, has been demonstrated to regulate Treg differentiation and stabilize nTreg in the healthy subjects. We here plan to determine whether atRA can similarly stabilize nTreg cells isolated from patients with active systemic lupus erythematosus (SLE) under inflammatory conditions.

Methods: CD4+CD25+CD127-/low human nTregs were sorted from PBMCs in patients with SLE or healthy controls, and then expanded in the presence or absence of atRA for 7 days. These cells were extensively washed and restimulated with or without IL-1β/IL-6 for additional 3 days. Cell suspensions were harvested for cytokine assay with Elisa and cells were stained with flow cytometry analysis. In vitro, suppression assay was performed, CD3+CD25–T cells labeled with carboxyfluorescein succinimidyl ester (CFSE) were stimulated with anti-CD3 in the presence of APC with or without different populations of nTreg cells. The CFSE dilution was examined by flow cytometry, and the suppression ratio was then calculated. Xenograft-vs-host diseases (xGVHD) models were conducted for determining the suppressive activities of Treg cells in vivo. NSG mice after γ-irradiation irradiation were injected with human CD25-depleted PBMCs with or without expanded SLE nTregs pretreated with atRA, rapamycin, DMSO control, and nTreg that had been exposed to IL-1β/IL-6. Mouse survival was monitored twice per week, and survival curves were analyzed by the log-rank test. Pathology in organ organs, human CD3+ engraftment and IgG were analyzed accordingly. The statistical comparisons were performed by the Student t test by using Prism software (GraphPad).

Results: In the presence of IL-1β/IL-6, atRA also prevents nTregs isolated from active SLE patients from converting to Th1 and/or Th17 cells and sustains their Foxp3 expression and suppressive function in vitro. atRA also diminished IL-1β/IL-6 signaling events by reducing STAT1, STAT3 activation. Adoptive transfer of SLE nTregs pretreated with atRA enhanced their suppressive function on xGVHDs, and only atRA primed nTregs sustained the suppressive effect on xGVHD after stimulation with IL-1β/IL-6.

Conclusion: Our results have demonstrated that atRA also stabilizes the Foxp3 expression and Treg function of patients with SLE, particularly on the inflammatory condition. Thus, a new protocol has been developed that usage of autologous atRA-programed Treg cells likely treats patients with SLE and other autoimmune diseases.


Disclosure: J. Wang, None; Z. Qiao, None; F. Huang, None; Y. Liu, None; N. J. Olsen, Mallinckrodt Pharmaceuticals, 2; S. G. Zheng, None.

To cite this abstract in AMA style:

Wang J, Qiao Z, Huang F, Liu Y, Olsen NJ, Zheng SG. All-Trans Retinoic Acid Stabilizes Natural T Regulatory Cells Isolated from Patients with Systemic Lupus Erythematosus Under Inflammatory Conditions [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/all-trans-retinoic-acid-stabilizes-natural-t-regulatory-cells-isolated-from-patients-with-systemic-lupus-erythematosus-under-inflammatory-conditions/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/all-trans-retinoic-acid-stabilizes-natural-t-regulatory-cells-isolated-from-patients-with-systemic-lupus-erythematosus-under-inflammatory-conditions/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology